OKYO PHARMA LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.48 USD | -0.88% |
|
-4.52% | -16.38% |
Valuation
| Fiscal Period: March | 2024 | 2025 |
|---|---|---|
| Capitalization 1 | 49.62 | - |
| Enterprise Value (EV) 1 | 49.62 | 49.62 |
| P/E ratio | -3.73 x | -3.93 x |
| Yield | - | - |
| Capitalization / Revenue | - | - |
| EV / Revenue | - | - |
| EV / EBITDA | - | - |
| EV / FCF | - | - |
| FCF Yield | - | - |
| Price to Book | - | - |
| Nbr of stocks (in thousands) | 33,236 | - |
| Reference price 2 | 1.493 | 1.493 |
| Announcement Date | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | - | -13.19 | -11.7 | -15.05 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | -11.7 | -15.05 |
| Net income 1 | -6.268 | - | -11.7 | -15.05 |
| Net margin | - | - | - | - |
| EPS 2 | - | - | -0.4000 | -0.3800 |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 22-08-15 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | -2.9 | -2.9 | -3 | - |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | -2.9 | -2.9 | -3 | - |
| Net income 1 | -2.9 | -2.9 | -3 | - |
| Net margin | - | - | - | - |
| EPS 2 | -0.1100 | -0.1000 | -0.0900 | -0.0900 |
| Dividend per Share | - | - | - | - |
| Announcement Date | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2022 | 2024 | 2025 |
|---|---|---|---|
| Net Debt | - | - | - |
| Net Cash position | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - |
| Free Cash Flow | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - |
| Assets 1 | - | - | - |
| Book Value Per Share | - | - | - |
| Cash Flow per Share | - | - | - |
| Capex | - | - | - |
| Capex / Sales | - | - | - |
| Announcement Date | 22-08-15 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.493
USD
Average target price
7
USD
Spread / Average Target
+368.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.38% | 49.62M | |
| -1.62% | 89.22B | |
| +1.32% | 40.49B | |
| -15.51% | 32.79B | |
| +64.13% | 26.23B | |
| -22.04% | 14.52B | |
| -7.58% | 13.09B | |
| -44.07% | 11.6B | |
| -13.06% | 11.5B | |
| +4.94% | 8.82B |
- Stock Market
- Equities
- EMMLD Stock
- Financials OKYO Pharma Limited
